{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:58Z","timestamp":1791559438517,"version":"4.3.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-metabotropic glutamate receptor 1 (mGluR1) encephalitis is a rare autoimmune disorder affecting both the central and peripheral nervous systems, typically characterized by a subacute cerebellar syndrome. Its effective treatment remains undefined. Here, we present the case of a 16-year-old male student who experienced dizziness upon walking and standing. Symptoms gradually worsened, leading to psychiatric and behavioral abnormalities. Neurological examination revealed somnolence, dysarthria, a broad-based unsteady gait, a prominent head tremor, and limb ataxia. The first magnetic resonance imaging scan showed no obvious abnormality. The background rhythm on the electroencephalogram was normal, with no epileptiform discharges observed. A whole-body PET\/CT scan revealed a mild reduction in glucose metabolism in the left frontal and temporal lobes. Lumbar puncture showed normal cerebrospinal fluid pressure but elevated white blood cell count and protein level. The diagnosis of anti-mGluR1 encephalitis was confirmed by positive anti-mGluR antibody testing, specifically showing an anti-mGluR1-IgG titer of 1:1000 in the cerebrospinal fluid and an anti-mGluR1-IgG1 titer of 10,000 in the serum. The patient did not respond to first-line therapy with corticosteroids. During disease progression, innovative sequential therapy with efgartigimod, an FcRn antagonist, was followed by the anti-CD20 monoclonal antibody rituximab (RTX) to reduce the risk of profound B-cell depletion. The patient exhibited significant clinical improvement, evidenced by a reduction in the Modified Rankin Scale (mRS) score from 4 to 3 and a decrease in the Scale for Assessment of Ataxia (SARA) score from 40 to 13. Efgartigimod effectively cleared pathogenic IgG, whereas RTX induced rapid B-cell depletion to prevent disease recurrence, thereby demonstrating synergistic efficacy. At the 12-month follow-up, the patient\u2019s clinical symptoms continued to improve, with no observed relapse. This case report underscores the importance of early diagnosis and therapeutic intervention, highlighting the need to suspect this condition based on its characteristic clinical presentation.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1928007","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:43Z","timestamp":1788417823000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: A case of anti-mGluR1 antibody-associated encephalitis treated with efgartigimod combined with rituximab"],"prefix":"10.3389","volume":"17","author":[{"given":"JunTong","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurology, Xi\u2019an International Medical Center Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WenPing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xi\u2019an International Medical Center Hospital","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tangdu Hospital, The Fourth Military Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1142160","article-title":"Anti-mGluR1 encephalitis: Case illustration and systematic review","volume":"14","author":"Khojah","year":"2023","journal-title":"Front Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/wco.0000000000000448","article-title":"CNS syndromes associated with antibodies against metabotropic receptors","volume":"30","author":"Lancaster","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000010854","article-title":"Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis","volume":"95","author":"Spatola","year":"2020","journal-title":"Neurology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00415-025-13356-x","article-title":"Autoimmune encephalitis with Anti-mGluR1 antibodies: a comprehensive review","volume":"272","author":"Chen","year":"2025","journal-title":"J Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/s1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2015.1115720","article-title":"Immune therapy in autoimmune encephalitis: a systematic review","volume":"15","author":"Nosadini","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10072-024-07843-8","article-title":"Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review","volume":"46","author":"Xu","year":"2025","journal-title":"Neurological Sci Off J Ital Neurological Soc Ital Soc Clin Neurophysiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24195","article-title":"Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis","volume":"76","author":"Moscato","year":"2014","journal-title":"Ann Neurol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41420-025-02459-z","article-title":"Immunotherapy for autoimmune encephalitis","volume":"11","author":"Cheng","year":"2025","journal-title":"Cell Death Discov"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01175-7","article-title":"Neonatal fc receptor-targeted therapies in neurology","volume":"19","author":"Nelke","year":"2022","journal-title":"Neurother J Am Soc For Exp Neurother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112137-20250308-00560","article-title":"Targeting neonatal Fc receptor blockade: reshaping the treatment landscape for IgG-mediated autoimmune diseases","volume":"105","author":"Wu","year":"2025","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard Jr","year":"2021","journal-title":"Lancet Neurol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e30421","article-title":"Efgartigimod as rescue treatment in acute phase of neuromyelitis optica spectrum disorder: A Case Report","volume":"10","author":"Li","year":"2024","journal-title":"Heliyon"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70534","article-title":"Safety and efficacy of a neonatal fc receptor antagonist in patients with anti-NMDAR encephalitis","volume":"31","author":"Bian","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2329048X221095695","DOI":"10.1177\/2329048x221095695","article-title":"A novel case of idiopathic MGluR1 encephalitis in a pediatric patient","volume":"9","author":"Chandler","year":"2022","journal-title":"Child Neurol Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1333658","article-title":"Cerebellar encephalitis associated with anti-mGluR1 antibodies: a case report and comprehensive literature review","volume":"15","author":"Chen","year":"2024","journal-title":"Front Neurol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.109229","article-title":"Clinical characteristics, treatment, and outcomes in anti-metabotropic glutamate receptor-1 encephalitis: A systematic review","volume":"259","author":"Li","year":"2025","journal-title":"Clin Neurol Neurosurg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12883-025-04345-8","article-title":"Efficacy of early rituximab treatment in anti-mGluR1 encephalitis: a case report","volume":"25","author":"Yamada","year":"2025","journal-title":"BMC Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/wco.0000000000001048","article-title":"Immunotherapy in autoimmune encephalitis","volume":"35","author":"Trewin","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334957","article-title":"Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae","volume":"96","author":"Thakolwiboon","year":"2025","journal-title":"J Neurology Neurosurgery Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2025.1580767","article-title":"Case Report: Clinical features and management of anti-mGluR1 encephalitis: case illustration and review of the literature","volume":"19","author":"Deng","year":"2025","journal-title":"Front Integr Neurosci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07460-5","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurological Sci Off J Ital Neurological Soc Ital Soc Clin Neurophysiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.20944\/preprints202511.0402.v1","article-title":"Efgartigimod for generalized myasthenia gravis and beyond: A narrative review of its pharmacological profile, clinical utility, and expanding applications","volume":"13","author":"Mansour","year":"2025","journal-title":"Biomedicines"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70308","article-title":"Efgartigimod as add-on treatment in refractory guillain-barr\u00e9 Syndrome: A case report","volume":"32","author":"Ripellino","year":"2025","journal-title":"Eur J Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1560483","article-title":"Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy","volume":"16","author":"Peng","year":"2025","journal-title":"Front Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2025.106983","article-title":"Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases","volume":"273","author":"Qin","year":"2025","journal-title":"Immunol Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurological Disord"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000200189","article-title":"The patient perspective in encephalitis research","volume":"11","author":"Finke","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1037\/t79580-000","article-title":"Scale for the assessment and rating of ataxia: development of a new clinical scale","volume":"66","author":"Schmitz-H\u00fcbsch","year":"2006","journal-title":"Neurology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1928007\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:48Z","timestamp":1788417828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1928007\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1928007"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1928007","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1928007"}}